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The ability of two fluoro-analogues of D-myo-inositol 1,4,5trisphosphate (Ins(l,4,5)P,) to mobilize intracellular CaZ+ stores in SH-SYSY neuro- 
blastoma cells has been investigated. DL-2-deoxy-2-fluoro-scyNoIns(l,4,5)P, (2F-Ins(l,4,5)P,) and DL-2,2-difluoro-2-deoxy-myo-Ins(l,4,5)P, (2 2- 
F,-Ins(l,4,5)P,) were full agonists (EC,,+ 0.77 and 0.41 PM respectively) and slightly less potent than D-Ins(l,4,5)P, (EC,, 0.13 PM), indicating 
that the axial 2-hydroxyl group of Ins(l,4,5)P, is relatively unimportant in receptor binding and stimulation of CaZf release. Both analogues mobi- 
lized CaZ+ with broadly similar kinetics and were substrates for Ins( 1,4,5)P, 3-kinase but, qualitatively, were slightly poorer than Ins( 1,4,5)P,. 2F- 
Ins(l,4,5)P, was a weak substrate for Ins(l,4,5)P, 5-phosphatase but 2,2-F,-Ins(l,4,5)P, was apparently not hydrolysed by this enzyme, although 
it inhibited its activity potently (4 = 26 PM). 
Second messenger; Inositol phosphate; Fluoro-analogue; CaZf mobilisation 
1. INTRODUCTION 
D-myo-inositol 1,4,5_trisphosphate (Fig. 1, (1)) is a 
second messenger which mediates the release of Ca2+ 
from intracellular stores [ 1,2] via a receptor which has 
been cloned and sequenced [3] and which, when 
reconstituted, mediates Ca2 + release in response to 
Ins(1,4,5)P3 [4]. A major challenge is now the elucida- 
tion of the structural basis for interaction of 
Ins(l,4,5)P3 both with its receptor and with the 
metabolic enzymes, Ins( 1,4,5)P3 3-kinase and 
5-phosphatase, and the rational chemical design of 
agonists, antagonists and enzyme inhibitors. Recent 
progress in inositol phosphate chemistry [5,6] and 
molecular recognition has been reviewed [7]. 
analogues of Ins( 1,4,5)P3, including DL-2-deoxy- 
Ins(1,4,5)P3 (Fig. 1 (2)), have appeared [13,14,15], but 
no biological evaluation of fluorinated inositol 
phosphates has yet been reported. 
We report here a study of the interaction of the two 
synthetic analogues 2-deoxy-2-fluoro-scyllo-inositol 
1,4,5-trisphosphate (2-F-Ins(l,4,5)P3) (Fig. 1, (3)) and 
2,2-difluoro-2-deoxy-myo-inositol 1,4,5_trisphosphate 
(2,2-F2-Ins(1,4,5)P$ (Fig. 1, (4)) with the 
Ca2 + -releasing receptor of SH-SYSY neuroblastoma 
cells and the metabolic enzymes Ins( 1,4,5)P3 
5-phosphatase and 3-kinase. 
Several inositol ring-modified and phosphate- 
modified analogues have been synthesized [5,6] and 
some progress has been made to understand the role of 
the 3 phosphate and hydroxyl groups of Ins(l,4,5)P3 in 
receptor binding specificity and stimulation. Isosteric 
replacement of a hydroxyl group with fluorine [8] has 
led to fluorinated myo-inositol [9, lo] and myo-inositol 
phosphate analogues [11,121. D-3-fluoro-3-deoxy-myo- 
inositol inhibits cell growth in NIH 3T3 cells [9] and 
5-fluoro-5-deoxy-myo-inositol is taken up by L1210 
cells and incorporated into cellular phospholipid [lo]. 
Three reports of biological activity for ring-modified 
2. MATERIALS AND METHODS 
2.1. Synthetic analogues 
DL-2-deoxy-2-fluoro-scyNo-inositol 1,4,5-trisphosphate (Fig. 1, 
(3)) and DL-2,2-difluoro-2-deoxy-myo-inositol 1,4,5_trisphosphate 
(Fig. 1, (4)) were synthesized from protected myo-inositol precursors 
by respective diethylaminosulphur trifluoride fluorination of 
l-prop-l-enyl-3,6-di-O-benzyl-4,5-O-isopropylidene-myo-inositol 
[16] and l-allyl-3,6-di-O-benzyl-4,5-O-isopropylidene-2-myo-inosose 
[16], removal of non-benzylic protecting groups, followed by 
bis(2-cyanoethyl)-N,N-diisopropylamino-phosphine phosphitylation, 
oxidation of the resulting trisphosphites with t-butyl hydroperoxide 
and deprotection using sodium in liquid ammonia, as described for 
Ins(l,4,5)P3 [17]. Analogues were purified on an ion-exchange col- 
umn of DEAE Sephadex A-25 using a gradient of triethylammonium 
bicarbonate buffers, pH 8.0, and were isolated as the triethylam- 
monium salt and assayed by quantitative phosphate analysis. Full 
chemical details of the synthetic procedures will appear elsewhere. 
Correspondence andpresent address: B.V.L. Potter, School of Phar- 2.2. Cell culture, permeabilisation and Cd’ release 
macy and Pharmacology, University of Bath, Claverton Down, Bath, Monolayers of SH-SYSY human neuroblastoma cells (passage 
BA2 7AY, UK 75-95), initially a kind gift of Dr J.L. Biedler (Sloane-Kettering In- 
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Fig. 1. Structures of synthetic analogues of lns(l,4,5)P3. Only D- 
isomers are shown. 
stitute, New York, USA), were grown as described [18]. Prior to 
permeabilisation, the cells were harvested in IO mM Hepes, 0.9% 
NaCl pH 7.4, containing 0.02% EDTA, electroporated [20] and 
%a’+ release experiments were performed as described [19]. The 
temporal characteristics of Ca* + mobilisation from electroporated 
SH-SYSY cells, maintained in the same buffer as for 45Ca2+ ex- 
periments, were monitored using a Ca* + -specific electrode [21]. All 
cell culture reagents were from GIBCO Ltd, D-lns(l,4,5)P3 was from 
Calbiochem, 45CaC12 (approx. 1000 Ci/mmol) was obtained from 
Amersham plc, ATP, quin-2 and oligomycin were obtained from 
Sigma. ECsa values were derived using ALLFIT computer-assisted 
curve fitting [22]. Combined data from a number of independent ex- 
periments (n) are expressed as mean + SEM, where n > 3. 
2.3. Ins(l,4,5)P3 5-phosphatase activity 
Human erythrocyte ghosts (7 mg protein/ml) were prepared accor- 
ding to Downes et al. [23] and stored at - 40°C. Protein concentra- 
tion was determined as described [25]. lns(l,4,5)Ps or fluoro- 
analogues (100 pM) were incubated at 37°C for 60 min in the presence 
of ghosts (5 mg protein/ml) or inactivated (boiled) ghosts in a buffer 
consisting of 30 mM Hepes, 2 mM MgCl2, pH 7.2. Incubations were 
terminated by boiling and lns(1,4,5)Ps and its analogues were then 
assayed for ability to release Ca 2+ from permeabilised SH-SYSY 
cells. Inhibition of 5[“P]-lns(l,4,5)P3 metabolism by 
2,2-F2-lns(l,4,5)P3 was performed essentially as described for inositol 
1,4,5trisphosphorothioate [24]. Erythrocyte ghosts (1 mg pro- 
tein/ml) were incubated at 37°C for 12 min in the presence of 30 gM 
lns(l,4,5)P3 (approx. 5000 dpm [“PI-lns(1,4,5)P3) and l-100 PM 
2,2-Fz-lns(l,4,5)P3. Under these conditions no more than 20% of the 
substrate was consumed. 
2.4. Ins(1,4,5)P3 -kinase activity 
Whole rat brains were minced, homogenised, diluted to a concen- 
tration of 20% w/v in 150 mM sucrose and centrifuged at 100 000 x g 
for 90 min. The resulting supernatant was stored at - 40°C until re- 
quired. lns(1,4,5)Ps or fluoro-analogues (1 mM) were incubated at 
37°C for 60 min in the presence of this crude 3-kinase preparation 
(5% w/v) or inactivated (boiled) enzyme preparation in a buffer con- 
sisting of 50 mM Tris-maleate, 20 mM MgClz, 10 mM NazATP, 5 mM 
2,3-bisphosphoglycerate, 0.1% BSA, pH 7.5. Incubations were ter- 
minated by boiling and the mixtures were assayed for ability to release 
4SCa2f from SH-SYSY cells. 
3. RESULTS AND DISCUSSION 
Myo-inositol possesses 5 equatorial hydroxyl groups 
and one axial hydroxyl group. Using fluorinated 
Ins(l,4,5)P3 analogues we have attempted to probe the 
role of the unique axial 2-hydroxyl group in determin- 
ing the affinity and specificity of Ins(1,4,5)P3 for its 
receptor and metabolic enzymes. The EC& of 
-_ 
o-1 
c ,W1 Phosphates 
Fig. 2. Dose-response curves for release of Ca” by lns(l,4,5)P3 and 
analogues in SH-SYSY neuroblastoma cells. For experimental details 
see section 2. 
Ins( 1,4,5)P3-induced Ca* + release in permeabilised SH- 
SYSY human neuroblastoma cells was 0.13 PM (Fig. 2, 
Table I). For DL-2,2-F2-Ins(1,4,5)P3 (Fig. 1, (4)) and 
DL-2F-Ins(l,4,5)P3 (Fig. 1, (3)) the ECso values were 
0.41 and 0.77 PM respectively (Fig. 2, Table I). Both 
analogues were full agonists for Ca* + mobilisation 
(Fig. 2) and released Ca*+ with kinetics similar to 
Ins(l,4,5)P3, although re-uptake of Ca*+ was slower 
for the analogues than for Ins(1,4,5)P3 (Fig. 3). 
These data suggest hat the analogues have slightly 
lower affinity than Ins(1,4,5)P3 for the receptor. This 
has also been confirmed by radioligand binding to the 
rat cerebellar Ins(1,4,5)P3 receptor (A.L. Willcocks, 
S.R. Nahorski and B.V.L. Potter, data not shown). It 
should be noted, however, that the synthetic fluoro- 
compounds are racemic mixtures. L-Ins( 1,4,5)P3 has 
previously been shown to be essentially inactive at bin- 
ding to and inducing Ca* + release at the stereospecific 
Table I 
Ca2+ release’ Fold shifts in ECse4 
EGO (pM) 3-kinase 5-phosphatase 
(n= 12) treatment’ treatment’ 
(n=3) (n = 3-4) 
D-lns(1,4,5)P3 0.13 + 0.01 24 Z!Z 6.5 10 t 3.4 
DL-2F-lns(1 ,4,5)P3 0.77 * 0.08 1.5 + 0.9 1.2 If- 0.3 
DL-2,2-Fz-lns(1,4,5)Ps 0.41 + 0.05 7 *3.0 0.2 rt 0.3 
I 45Ca2 + release from permeabilised SH-SYSY neuroblastoma cells 
’ After 1 h treatment of lns(1,4,5)P3 or analogue (1 mM) with 5% 
3-kinase preparation 
3 After 1 h treatment of lns(1,4,5)P3 or analogue (100 PM) with 5 mg 
protein/ml 5-phosphatase at 37°C 
4 Fold shifd is defined by ([ECSo(after)/ECso(before)] -1) 
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Fig. 3. Kinetics of Ca2+ release induced by Ins(l,4,5)P3 and synthetic fluoro-analogues monitored in electrically permeabilised SH-SYSY 
neuroblastoma cells using a Ca’+ -specific electrode. Suspensions of permeabilised cells (3-4 mg protein/ml) were challenged with 5 pM D- 
Ins(l,4,5)Ps (I) and (a) 5 pM and 10 gM 2,2-F2_Ins(1,4,5)Pj or (b) 5 CM and 10 pM 2F-Ins(1,4,5)Ps. Data shown are representative of results from 
3 similar independent experiments. 
Ins( 1,4,5)P3 receptor [7]. Thus, the true EC50 values for 
D-2,2-Fz-Ins( 1,4,5)P3 and D-2F-Ins( 1,4,5)P3 may be 
taken as 0.21 PM and 0.39 ,uM respectively and fluoro- 
substitution at the 2-position therefore makes the 
analogues only some 1.6- and 3-fold less potent than 
Ins(1,4,5)P3. 
These data should be compared with an EC50 of 6 PM 
for D-6-deoxy-Ins(l,4,5)Ps_induced Ca2 + release in 
SH-SYSY cells (J. Strupish, S. Safrany, D. Dubreuil, 
S.D. Gero, S.R. Nahorski and B.V.L. Potter, un- 
published observations) and with an EC50 of 0.5 PM 
reported for DL-2-deoxy-Ins(l,4,5)Ps_induced Ca2 + 
release (i.e. 0.25 PM for the D-isomer compared with 
0.2 PM for D-Ins(l,4,5)P3) in permeabilised 
macrophages [141. Qualitatively, therefore, there is lit- 
tle difference between the 2-deoxy and 2-fluorinated 
analogues and since the EC50 values are only slightly 
higher than Ins(1,4,5)P3 itself, the axial 2-hydroxyl, in 
contrast to the 6-hydroxyl group, cannot be making a 
major contribution to receptor binding and activation. 
This is also borne out by the tolerance of the Ca2+ 
mobilising receptor for certain bulky substitutions at 
the 2-position [ 14,151. 
The three phosphate groups of Ins( 1,4,5)P3 will most 
likely make ionic interactions with positively charged 
centres of the Ins(l,4,5)P3 receptor and make the major 
contribution to binding energy. The three hydroxyl 
groups at the 2, 3, and 6 positions will be either 
hydrogen bond donors to the protein, or acceptors of 
hydrogen bonds from it. Complete deletion of single or 
multiple hydroxyl groups can lead to drastic loss 
of Ca2+ -mobilising ability, exemplified by the 
low potency of D-6-deoxy-Ins( 1,4,5)P3 and 
DL- 1,2,4-cyclohexane trisphosphate [ 131, but ap- 
parently not for 2-deoxy-Ins( 1,4,5)Ps (Fig. 1, (2)) [ 141. 
Isosteric and isoelectronic replacement of a hydroxyl 
group by fluorine [8], however, might be predicted to 
have a less drastic effect, provided H-bonding interac- 
tions could still be made with the protein. 
2,2-Fz-Ins(l,4,5)P3 and 2F-Ins(l,4,5)Ps differ struc- 
turally only by the fact that the former possesses an ax- 
ial fluorine atom rather than a proton and is therefore 
unable to donate a hydrogen bond. 2,2-Fz-Ins( 1,4,5)Ps 
is clearly a more potent analogue than 2F-Ins(l,4,5)P3, 
presumably since the axial fluorine atom is able to make 
a more favourable interaction with the receptor and, in- 
deed, this analogue is only marginally (1.6-fold) less po- 
tent than Ins(1,4,5)P3 itself. We propose, therefore, 
that the 2-hydroxyl group of Ins(1,4,5)P3 accepts a 
hydrogen bond from the receptor 
Ins(1,4,5)P3 is metabolised by two major routes: 
phosphorylation by a 3-kinase and dephosphorylation 
by a 5-phosphatase [7]. Treatment of solutions of 
Ins(l,4,5)P3 or fluoro-analogues with a 3-kinase 
preparation, followed by assay of Ca2 + -releasing abili- 
ty, gave shifts in EC50 on account of 3-position 
phosphorylation as shown (Table I). Clearly, both 
fluoro-analogues are weaker substrates than 
Ins(l,4,5)P3 for the 3-kinase, but 2,2-F2_Ins(l,4,5)P3 
appeared to be significantly better than 2F- 
Ins(1,4,5)P3, presumably since the axial fluorine atom 
of the former acts more successfully to mimic the nor- 
mal electronic environment at the 2-position adjacent o 
the crucial 3-hydroxyl group. Whilst not an absolute re- 
quirement for activity, the 2-hydroxyl group is clearly 
an important element in the recognition of substrates by 
Ins( 1,4,5)P3 3-kinase. 
We have also investigated the interaction of the 
fluoro-analogues with Ins(l,4,5)P3 5-phosphatase from 
human erythrocyte ghosts. Treatment of solutions of 
Ins(l,4,5)P3 or fluoro-analogues with a 5-phosphatase 
preparation, followed by assay of Ca2 + -releasing abili- 
ty, gave shifts in ECK,, on account of dephosphoryla- 
tion as shown (Table I). Thus, whilst 2F-Ins(1,4,5)P3 
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appears to be a weaker substrate for 5-phosphatase 
than Ins( 1,4,5)P3, there was no significant shift in E&J 
value for 2,2-Fz-Ins(1,4,5)P3. This is surprising, on ac- 
count of the known low specificity of 5-phosphatase for 
substrates [7,131. Moreover, a study of 
2,2-Fz-Ins(l,4,5)P3_induced inhibition of 
5[32P]Ins(1,4,5)P3 breakdown by erythrocyte 
5-phosphatase (data not shown; method similar to [24]) 
showed that this analogue binds to the enzyme with 
high affinity (Ki = 26 +4.1 PM; cf. K, for D- 
Ins(l,4,5)P3, 40 /JM [24]). While Ins( 1,4,5)P3 
5-phosphatase is specific for the D-enantiomer of 
Ins(1,4,5)P3, the analogue is a racemate and this unex- 
pected result may indicate that L-2,2-F2-Ins(l,4,5)P~ 
has a considerably higher affinity for 5-phosphatase 
than would be expected (cf. Ki for L-Ins(l,4,5)P3, 124 
PM [24]) and is inhibiting breakdown of 
D-2,2-F2_Ins(l,4,5)P3. This seems plausible in the light 
of data showing that a 2-arylacyl-substituted L- 
Ins( 1,4,5)P3 analogue was a highly potent inhibitor of 
5-phosphatase with a Ki of 3.8 PM [ 151. Further analysis 
must await resolution of the pure enantiomers of 
2,2-Fz-Ins(1,4,5)P3. The slow hydrolysis of 2F- 
Ins(1,4,5)P3 is also in accord with the observation that 
2-deoxy-Ins(l,4,5)P3 is hydrolysed more slowly than 
Ins(1,4,5)P3 by both erythrocyte ghost and brain 
cytosol5-phosphatase [14]. Our results support the no- 
tion that the 2-hydroxyl group of Ins( 1,4,5)P3 is not ab- 
solutely required for activity, but it may be involved in 
substrate recognition by Ins(1,4,5)P3 5-phosphatase. 
The metabolism of the fluoro-analogues was examin- 
ed using electrically-permeabilised SH-SYSY cells, 
which exhibit both Ins(1,4,5)Ps 5-phosphatase and 
3-kinase activities [26]. 2,2-F2-Ins(l,4,5)P3 and 2F- 
Ins(l,4,5)P3 gave similar Ca2+ -release profiles to that 
induced by Ins(1,4,5)P3, but Ca2+ re-uptake, which 
parallels inositol phosphate metabolism, was retarded 
(fig. 3); e.g. for 5 PM D-Ins(l,4,5)P3 the time taken for 
Ca2 + concentration to decay to 50% of the maximal 
response was on average 2.8 min, whereas for 10 PM 
DL-2,2-Fz-Ins(l,4,5)P3 the time taken was 5.4 min. 
This is consistent with a combination of the effects of 
5-phosphatase and 3-kinase already demonstrated. 
We conclude that both analogues are recognized by 
all three Ins(1,4,5)P3 binding proteins and that the 
2-hydroxyl group of Ins(1,4,5)P3 does not play an ab- 
solute role either in receptor binding and activation, or 
enzyme activity, although it may be an important 
recognition element. 
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